McEvoy], Gerald K.; [et al] (2010). AHFS drug information 2010. Bethesda, MD: American Society of Health-System Pharmacists. ISBN9781585282470. Consultado el 8 de febrero de 2018.
doi.org
dx.doi.org
Reeves, RR; Carter, OS; Pinkofsky, HB; Struve, FA; Bennett, DM (de de 1999). «Carisoprodol (soma): abuse potential and physician unawareness.». Journal of addictive diseases18 (2): 51. PMID10334375. doi:10.1300/J069v18n02_05.|fechaacceso= requiere |url= (ayuda)
Gatch, Michael B.; Nguyen, Jacques D.; Carbonaro, Theresa; Forster, Michael J. (Junio de 2012). «Carisoprodol tolerance and precipitated withdrawal». Drug and Alcohol Dependence123 (1-3): 29-34. doi:10.1016/j.drugalcdep.2011.10.010.|fechaacceso= requiere |url= (ayuda)
Tse, SA; Atayee, RS; Best, BM; Pesce, AJ (Mayo de 2012). «Evaluating the relationship between carisoprodol concentrations and meprobamate formation and inter-subject and intra-subject variability in urinary excretion data of pain patients.». Journal of analytical toxicology36 (4): 221-31. PMID22511696.|fechaacceso= requiere |url= (ayuda)
Reeves, RR; Carter, OS; Pinkofsky, HB; Struve, FA; Bennett, DM (de de 1999). «Carisoprodol (soma): abuse potential and physician unawareness.». Journal of addictive diseases18 (2): 51. PMID10334375. doi:10.1300/J069v18n02_05.|fechaacceso= requiere |url= (ayuda)
Heacock, C; Bauer, MS (1 de abril de 2004). «Tolerance and dependence risk with the use of carisoprodol.». American family physician69 (7): 1622-3. PMID15086035.